Emblaveo, developed by Pfizer and approved today by the European Commission, can be used to treat complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections caused by certain types of drug-resistant bacteria. “This newly approved medicine will fill an important gap where there are currently a very limited number of treatment options,” said the EU executive in a press release. This authorisation comes a month after the European Medicines Agency adopted a positive opinion and recommended its marketing authorisation. The antibiotic was evaluated under EMA…